An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients with Already Manufactured DCVax-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221.
ClinicalTrials.gov Identifier: NCT02146066
UCLA IRB #: 14-001090
Sponsor: Northwest Biotherapeutics
Time Frame: up to 3 years
Purpose: The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific enrollment criteria. Patients will receive therapy per investigator discretion (standard of care) as well as active vaccine per the 020221 protocol administration schedule. It is estimated that approximately 99 patients will enroll in this study.
Principal Investigator: Linda Liau, MD, PhD, MBA
Contact: Emma Billingslea-Yoon, N.P.
Phone: (310) 267-0373